![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Ledipasvir/Sofosbuvir Fixed-Dose Combination
Is Safe and Effective in Difficult-to-Treat Populations Including GT 3 Patients, Decompensated GT 1 Patients,
and GT 1 Patients With Prior Sofosbuvir Experience
|
|
|
Reported by Jules Levin
EASL 2013 April 9-13 London, UK
Edward J. Gane,1 Robert H. Hyland,2 Di An,2 Phillip S. Pang,2 William T.
Symonds,2 John G. McHutchison,2 Catherine A. Stedman3
1Auckland Clinical Studies Ltd, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, CA, USA; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand
![EASL1.gif](../images/041114/041114-16/EASL1.gif)
![EASL2.gif](../images/041114/041114-16/EASL2.gif)
![EASL3.gif](../images/041114/041114-16/EASL3.gif)
![EASL4.gif](../images/041114/041114-16/EASL4.gif)
![EASL5.gif](../images/041114/041114-16/EASL5.gif)
![EASL6.gif](../images/041114/041114-16/EASL6.gif)
![EASL7.gif](../images/041114/041114-16/EASL7.gif)
![EASL8.gif](../images/041114/041114-16/EASL8.gif)
![EASL9.gif](../images/041114/041114-16/EASL9.gif)
![EASL10.gif](../images/041114/041114-16/EASL10.gif)
![EASL11.gif](../images/041114/041114-16/EASL11.gif)
![EASL12.gif](../images/041114/041114-16/EASL12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|